Evaluation of the Anticoagulant Efficacy and Safety of Nafamostat Mesylate in Hemodialysis Patients
Objective: To evaluate the anticoagulant efficacy and safety of nafamostat mesylate (NM) in patients undergoing hemodialysis, aiming to provide clinical guidance for its application. Methods: From January 2023 to December 2024, a total of 60 patients undergoing hemodialysis at the Department of Nephrology, Wuxi Ninth People’s Hospital, were randomly assigned to either the observation group (NM group) or the control group (standard anticoagulant), with 30 patients in each group. The anticoagulant efficacy, coagulation function, acid-base balance, and plasma electrolyte levels were compared between the two groups. Results: The overall anticoagulant efficacy in the NM group was 90.0%, significantly higher than 60.0% in the control group (p < 0.001). Fibrin deposition in the dialyzer and tubing was less in the NM group, and coagulation function remained more stable (p > 0.05). After 2 and 4 hours of dialysis, the activated partial thromboplastin time (APTT) in the NM group was significantly prolonged (p < 0.05). There were no significant differences in pH, Na+, and K+ levels between the two groups before and after dialysis (p > 0.05). Fewer bleeding complications were observed in the NM group compared to the control group, with no serious adverse reactions reported. Conclusion: Nafamostat mesylate demonstrates superior anticoagulant efficacy compared to traditional anticoagulants in hemodialysis, with a higher safety profile. NM effectively prevents fibrin deposition during dialysis, maintains the patency of the dialyzer, reduces bleeding risks, and is suitable for patients at high risk of bleeding during hemodialysis.
[1] George C, Kengne A, 2024, Advances in the Diagnosis, Treatment, and Prognosis of Chronic Kidney Disease: A Reflection on Recent Developments. Applied Sciences, 14(13): 5518.
[2] Kameda S, Fujii T, Ikeda J, et al., 2023, Unfractionated Heparin Versus Nafamostat Mesylate for Anticoagulation During Continuous Kidney Replacement Therapy: An Observational Study. BMC Nephrology, 24(1): 12.
[3] Kameda S, Maeda A, Maeda S, et al., 2024, Dose of Nafamostat Mesylate During Continuous Kidney Replacement Therapy in Critically Ill Patients: A Two-Centre Observational Study. BMC Nephrology, 25(1): 69.
[4] Liu D, Zhao J, Xia H, et al., 2024, Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Retrospective Single-Center Study. European Journal of Medical Research, 29(1): 72.
[5] Smythe M, Priziola J, Dobesh P, et al., 2016, Guidance for the Practical Management of the Heparin Anticoagulants in the Treatment of Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 41: 165–186.
[6] Crowther M, Warkentin T, 2008, Bleeding Risk and the Management of Bleeding Complications in Patients Undergoing Anticoagulant Therapy: Focus on New Anticoagulant Agents. Blood, 111(10): 4871–4879.
[7] Yang Z, Chen Q, Li Q, et al., 2024, Application of Nafamostat Mesylate for Extracorporeal Anticoagulation in Hemodialysis Patients at High Risk of Bleeding. Chinese Journal of Blood Purification, 23(9): 651–654 + 662.
[8] Chen P, Zhao L, Huang L, et al., 2023, Nafamostat Mesilate Prevented Caerulein-Induced Pancreatic Injury by Targeting HDAC6-Mediated NLRP3 Inflammasome Activation. Inflammation Research, 72(9): 1919–1932.
[9] Jiang Q, Wang B, Zhang M, et al., 2024, Application of Nafamostat Mesylate Anticoagulation in Hemodialysis for Patients with Delayed Graft Function After Kidney Transplantation. Chinese Journal of Integrated Traditional and Western Nephrology, 25(8): 698–700.
[10] Tsujimoto Y, Fujii T, 2022, How to Prolong Filter Life During Continuous Renal Replacement Therapy? Critical Care, 26(1): 62.
[11] Qian Y, Wu W, Wang M, et al., 2024, How Do Filter Types of Renal Replacement Therapy Affect Survival in Critically Ill Patients? Concerns About Adsorption of Nafamostat Mesylate on AN69 Membranes. BMC Nephrology, 25(1): 314.
[12] Tang J, Yang L, Wang J, et al., 2024, Nafamostat Mesylate Has Advantages as an Anticoagulant for Patients Undergoing Maintenance Hemodialysis with Conjunctival Bleeding. Clinical Kidney Journal, 17(7).
[13] Chen S, Huang Y, Yang K, 2024, Comparative Study on the Efficacy and Safety of Nafamostat Mesylate Versus Citrate Anticoagulation in CRRT for Patients at High Bleeding Risk. Journal of Practical Shock (Chinese and English), 8(2): 89–92 + 103.
[14] Zhang Y, Chen X, Lao Y, et al., 2023, Using Nafamostat Mesilate Anticoagulation for Continuous Renal Replacement Therapy in High Bleeding Risk Patients: A Systematic Review and Meta-Analysis.\
[15] Zhuang B, Ye H, Cao H, et al., 2022, A Multicenter Randomized Controlled Study of Nafamostat Mesylate for Injection in Anticoagulation Therapy for Hemodialysis. Chinese Journal of Blood Purification, 21(10): 739–743.
